ReviewMolecular biology reports2026
Quercetin as a multi-targeted therapeutic candidate in oral cancers: molecular mechanisms and preclinical evidence.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral malignancies, particularly oral squamous cell carcinoma (OSCC), are among the most prevalent head and neck cancers and remain associated with high morbidity, therapeutic resistance, and frequent recurrence. Despite multimodal treatment approaches, long-term survival remains suboptimal, highlighting the need for novel adjunctive strategies. Quercetin, a naturally occurring dietary flavonoid abundant in fruits and vegetables, has attracted attention due to its antioxidant, anti-inflammatory, and anticancer properties, with growing evidence supporting its relevance in oral cancer. In vitro studies demonstrate that quercetin significantly reduces oral cancer cell viability, proliferation, and clonogenic potential in a dose- and time-dependent manner. These effects are mediated by modulation of key cell-cycle regulators, resulting in arrest at the G1 and G2/M phases. Quercetin also promotes apoptosis through increased intracellular reactive oxygen species (ROS) generation, mitochondrial membrane depolarization, cytochrome c release, and activation of caspase-9 and caspase-3, indicating involvement of the intrinsic pathway. Concurrent activation of Fas/Fas-L signaling and caspase-8 suggests engagement of the extrinsic apoptotic pathway as well. Beyond cytotoxicity, quercetin suppresses migration and invasion by inhibiting epithelial-mesenchymal transition (EMT), characterized by increased E-cadherin and reduced N-cadherin and vimentin expression. It also downregulates MMP-2, MMP-9, and VEGF, thereby limiting extracellular matrix degradation and angiogenesis. In vivo studies further confirm reductions in tumor volume and growth kinetics without significant systemic toxicity. Nonetheless, although these findings underscore quercetin's multi-targeted anticancer potential, clinical translation is limited by poor bioavailability and rapid metabolism. Optimized delivery systems and well-designed clinical trials are necessary to clarify its therapeutic applicability in oral malignancies. This review will summarize current evidence on quercetin's anticancer effects in oral malignancies and highlight the molecular mechanisms underlying its therapeutic potential.
Indexed as
Identifiers
42234050What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.